PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Lung cancer is the second-most commonly diagnosed cancer and the leading cause of
cancer death worldwide. The most common histological type is non-small-cell lung cancer …

Purpose To update literature-based recommendations for techniques used in high-precision
thoracic radiotherapy for lung cancer, in both routine practice and clinical trials. Methods A …

PURPOSE This trial aimed to assess the efficacy and safety of the paclitaxel plus fluorouracil
regimen versus the cisplatin plus fluorouracil regimen in definitive concurrent …

The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of early and locally-advanced …

Background: Non-small cell lung cancer (NSCLC) is the most prevalent cancer in the world.
Chemotherapy resistance is a major obstacle to NSCLC therapy. This study explored the …

For more than a decade, there has been no improvement in outcomes for patients with
unresectable locally advanced (LA) non-small-cell lung cancer (NSCLC). The standard …

Podophyllotoxin (PPT) has attracted researchers' attention because of its ability to treat
various ailments. A series of podophyllotoxin derivatives (PPTs) have been synthesized as …

Purpose Concurrent chemoradiotherapy is standard treatment for patients with stage III non–
small-cell lung cancer. Elderly patients may experience increased rates of adverse events …

Ca2+ release from the endoplasmic reticulum (ER) is an essential event in the modulation of
Ca2+ homeostasis, which is coordinated by multiple biological processes, ranging from cell …